CASi-004

CASi-004 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Switch Therapeutics. It is built upon the company's proprietary Conditionally Activated siRNA (CASi) platform, which utilizes a unique RNA architecture designed to remain inactive until it reaches the target cell or tissue environment. This platform is specifically engineered for efficient delivery and potent gene silencing in the central nervous system (CNS) and other systemic tissues. While the specific molecular target and primary indication for CASi-004 have not been publicly disclosed, the program represents part of a pipeline focused on addressing high unmet needs in neurological disorders through precise, switchable RNA interference.